FDA Approves PROSCAR — Organon LLC

# FDA Approves Organon's PROSCAR (Finasteride) for Oral Use Organon LLC received FDA approval for PROSCAR (finasteride), an oral medication that is expected to capture significant market share in the treatment of benign prostatic hyperplasia and establish a new therapeutic category for hormonally-driven conditions affecting the urological market. The approval positions Organon as a key player in the men's health pharmaceutical space, with potential for substantial revenue generation from this first-in-class therapeutic approach.